Programmable VT detection enhancements in implantable cardioverter defibrillator therapy

Influence of myopotential interference on the Wavelet discrimination algorithm in implantable cardioverter-defibrillator

Background

Wavelet is a morphology-based algorithm for detecting ventricular tachycardia. The electrogram (EGM) source of the Wavelet algorithm is nominally programmed with the Can-RV coil configuration, which records a far-field ventricular potential. Therefore, it may be influenced by myopotential interference.

Methods

We performed a retrospective review of 40 outpatients who had an implantable cardioverter-defibrillator (ICD) with the Wavelet algorithm. The percent-match score of the Wavelet algorithm was measured during the isometric chest press by pressing the palms together. We classified patients with percent-match scores below 70% due to myopotential interference as positive morphology change, and those with 70% or more as negative morphology change. Stored episodes of tachycardia were evaluated during the follow-up.

Results

The number of patients in the positive morphology change group was 22 (55%). Amplitude of the Can-RV coil EGM was lower in the positive morphology change group compared to that in the negative group (3.9±1.3 mV vs. 7.4±1.6 mV, P=0.0015). The cut-off value of the Can-RV coil EGM was 5 mV (area under curve, 0.89). Inappropriate detections caused by myopotential interference occurred in two patients (5%) during a mean follow-up period of 49 months, and one of them received an inappropriate ICD shock. These patients had exhibited positive morphology change.

Conclusions

The Wavelet algorithm is influenced by myopotential interference when the Can-RV coil EGM is less than 5 mV.

Inappropriate Implantable Cardioverter-Defibrillator Therapy

Although improvements in implantable cardioverter-defibrillator (ICD) therapy have taken place, many challenges do remain. Inappropriate delivery of therapy is a big problem that impacts the quality of life of ICD recipients. Although there is now a clear understanding that atrial arrhythmias are the main cause of inappropriate ICD therapies, physicians have not been very successful in preventing them. Additionally, although many tachycardia detection discriminators have been shown to be helpful, it is not clear that there is a particular combination that is ideal for all patients. Until such an algorithm is developed (which may not be possible), a detailed knowledge and use of all available programming options, guided by special characteristics of each unique patient, are the only foreseeable solutions. Finally, one must face the prospect that this problem cannot be vanquished, but only ameliorated.

Improving SVT Discrimination in Single-Chamber ICDs: A New Electrogram Morphology-Based Algorithm

INTRODUCTION

Wide-spread adoption of ICD therapy has focused efforts on improving the quality of life for patients by reducing "inappropriate" shock therapies. To this end, distinguishing supraventricular tachycardia from ventricular tachycardia remains a major challenge for ICDs. More sophisticated discrimination algorithms based on ventricular electrogram morphology have been made practicable by the increased computational ability of modern ICDs.

METHODS AND RESULTS

We report results from a large prospective study (1,122 pts) of a new ventricular electrogram morphology tachycardia discrimination algorithm (Wavelet Dynamic Discrimination, Medtronic, Minneapolis, MN, USA) operating at minimal algorithm setting (RV coil-can electrogram, match threshold of 70%). This is a nonrandomized cohort study of ICD patients using the morphology discrimination of the Wavelet algorithm to distinguish SVT and VT/VF. The Wavelet criterion was required ON in all patients and all other supraventricular tachycardia discriminators were required to be OFF. Spontaneous episodes (N = 2,235) eligible for ICD therapy were adjudicated for detection algorithm performance. The generalized estimating equations method was used to remove bias introduced when an individual patient contributes multiple episodes. Inappropriate therapies for supraventricular tachycardia were reduced by 78% (90% CI: 72.8-82.9%) for episodes within the range of rates where Wavelet was programmed to discriminate. Sensitivity for sustained ventricular tachycardia was 98.6% (90% CI: 97-99.3%) without the use of high-rate time out.

CONCLUSIONS

Results from this prospective study of the Wavelet electrogram morphology discrimination algorithm operating as the sole discriminator in the ON mode demonstrate that inappropriate therapy for supraventricular tachycardia in a single-chamber ICD can be dramatically reduced compared to rate detection alone.

R-wave detection by subcutaneous ECG. Possible use for analyzing R-R variability

BACKGROUND

Atrial arrhythmia (AA) discrimination remains a technological challenge for implanted cardiac devices. We examined the feasibility of R-wave detection by a subcutaneous far field ECG (SFFECG) and analysis of these signals for R to R variability as an indicator of atrial arrhythmia (AA).

METHODS

Surface ECG and SFFECG (from the pacemaker pocket) were recorded in sixteen patients (61.5 +/- 11.4 years) with AA. The SFFECG was recorded with a pacemaker sized four electrode array acutely placed in the pacemaker pocket during implantation. The signals were analyzed to obtain peak-to-peak R wave amplitude and R to R interval variability (indicative of AAs).

RESULTS

In sixteen patients R waves were visually discernible in all recordings. The percentage over and under detection for automatic R wave recognition SFFECG was 3 and 9%, respectively. R to R variability analysis using the SFFECG produced results concordant to those using the surface ECG.

CONCLUSION

SFFECG might be a helpful adjunct in implantable device systems for detection of R waves and may be used for measurement of R to R variability.

The Rhythm ID Going Head to Head Trial (RIGHT): Design of a Randomized Trial Comparing Competitive Rhythm Discrimination Algorithms in Implantable Cardioverter Defibrillators

BACKGROUND

The implantable cardioverter defibrillator (ICD) has become primary therapy for the prevention of sudden death. One of the major morbidities of ICD use remains inappropriate therapy for supraventricular arrhythmias (SVA). Detection enhancements have increased therapy specificity, but their impact on inappropriate therapy is not well studied. Moreover, ICD manufacturers have developed unique algorithms to meet this goal, with no previous clinical direct comparisons. RIGHT is a randomized, prospective study that will assess the differential efficacy of ICDs from two different manufacturers. It is the first trial to compare directly competitive ICD rhythm discrimination algorithms on a large scale.

OBJECTIVE

The primary objective of this study is to assess arrhythmia discrimination in Guidant versus Medtronic ICDs by comparing the time to first inappropriate therapy after the predischarge visit.

METHODS

The study will enroll approximately 2,000 patients in 100 centers. Patients will be randomized to Guidant or Medtronic using a permuted block design, stratified by center and by single/dual chamber device types. Patients will receive a commercially available Guidant VITALITY 2 family ICD with Rhythm ID or a Medtronic ICD using the Enhanced PR Logic or Wavelet discrimination algorithms, and will be followed according to the schedule shown until a common closing date with a minimum follow-up of 12 months. All events will be reviewed by an independent committee to determine the appropriateness of rhythm classification and therapy delivery.

CONCLUSION

RIGHT is the first randomized, large scale, head-to-head comparison of ICD discrimination algorithms.

Electrogram configuration and detection of supraventricular tachycardias by a morphology discrimination algorithm in single chamber ICDs

BACKGROUND

Inappropriate ICD therapy for supraventricular tachycardia (SVT) remains a significant problem. A morphology-based algorithm (Wavelet) compares baseline and tachycardia electrograms (EGM). For this analysis different EGM sources can be programmed. This study evaluates the performance of Wavelet using two different EGM configurations (SVC-Can and RV-Can) for the detection of exercise-induced SVT.

METHODS

Patients with a Medtronic model 7230 single chamber ICD and a dual coil lead were included. For each EGM source (SVC-Can or RV-Can), a baseline EGM template was acquired and the morphology similarity to this template (match percentage) was evaluated for 10-15 beats at different heart rates during exercise testing. The lower VT detection limit was programmed to 600 ms (therapies off).

RESULTS

A total of 28 patients (66.9 +/- 4.7 years, 93% men) and 5,824 intracardiac QRS complexes were analyzed. With the RV-Can source, a consistently high similarity to the baseline EGM template was observed (< or =100 bpm: 90.90 +/- 0.56%; >100 bpm: 90.24 +/- 0.55%, P > 0.05). In contrast, SVC-Can was associated with a lower match percentage at baseline and a significant decrease at higher heart rates (< or =100 bpm: 77.91 +/- 2.65%; >100 bpm: 59.05 +/- 5.65%, P < 0.005). Accordingly, the specificity for appropriate detection of exercise-induced SVT was higher with RV-Can (21/21 episodes) than with SVC-Can (8/18 episodes, specificity 100% vs 44%; P < 0.0001).

CONCLUSION

The RV-Can configuration appears to be superior to SVC-Can as EGM source for appropriate SVT detection with the Wavelet algorithm.

Development of an algorithm for detection of fatal cardiac arrhythmia for implantable cardioverter-defibrillator using a self-organizing map

In this study, we have introduced the pattern classifier using the self-organizing map (SOM) for detecting fatal cardiac arrhythmia in implantable cardioverter-defibrillators (ICDs). The SOM has learned patterns of sinus rhythm, ventricular fibrillation and ventricular tachycardia with the feature vectors extracted from electrocardiogram and right ventricular volume measured during an arrhythmia induction experiment of a dog. After learning, neurons of the SOM were labeled by using the k-Nearest Neighbor method. It was shown that the accuracy of the proposed method was higher than other competitive methods applied to the same test data.

Clinical Results of an Advanced SVT Detection Enhancement Algorithm

INTRODUCTION

Supraventricular tachycardia (SVT) has many characteristics that are similar to ventricular tachycardia (VT). This presents a significant challenge for the SVT-detection algorithms of an implantable cardioverter defibrillator (ICD). A newly developed ICD, which utilizes a Vector Timing and Correlation algorithm as well as interval-based conventional SVT discrimination algorithms (Rhythm ID), was evaluated in this study.

MATERIALS AND METHODS

This study was a prospective, multicenter trial that evaluated 96 patients implanted with an ICD at 21 U.S. centers. All patients were followed at 2 weeks, 1 month, and every 3 months post implant. A manual Rhythm ID reference vector was acquired prior to any arrhythmia induction. During testing, atrial tachyarrhythmias were induced first, followed by ventricular arrhythmia induction. Induced and spontaneous SVT and VT/ventricular fibrillation (VF) episodes recorded during the trial were annotated by physician investigators.

RESULTS

The mean age of the patients implanted with an ICD was 67.3 +/- 10.8 years. Eighty-one percent of patients were male. The primary cardiovascular disease was coronary artery disease, and the primary tachyarrhythmia was monomorphic VT. Implementation of the Rhythm ID algorithm did not affect the VT/VF detection time. There were a total of 370 ventricular tachyarrhythmias (277 induced and 93 spontaneous) and 441 SVT episodes (168 induced and 273 spontaneous). Sensitivity for ventricular tachyarrhythmias was 100%, and specificity for SVT was 92% (94% and 91% for induced and spontaneous SVT, respectively). All patients had a successful manual Rhythm ID acquisition prior to atrial tachyarrhythmia induction. At the 1-month follow-up, the Rhythm ID references were updated automatically an average of 167.8 +/- 122.7 times. Stored Rhythm ID references correlated to patients' normally conducted rhythm 100% at 2 weeks, and 98% at 1 month.

CONCLUSIONS

The Rhythm ID algorithm achieved 100% sensitivity for VT/VF, and 92% specificity for SVT. The manual and automatic Rhythm ID update algorithms successfully acquired references, and the updated references were highly accurate.

Optimal Combination of Discriminators for Differentiating Ventricular from Supraventricular Tachycardia by Dual-Chamber Defibrillators

Discriminators for ventricular/supraventricular tachycardia.

INTRODUCTION

Dual-chamber implantable cardioverter defibrillators (ICDs) use discriminators to differentiate between supraventricular tachycardias (SVTs) and ventricular tachycardias (VT), the accuracy of which may depend on the type and method used. ICDs can combine rate branching of tachyarrhythmias according to their A:V relationship with two SVT-VT discriminators in each rate branch, using ANY (either) or ALL (both) logic. Our goal was to determine the optimal discriminator combination.

METHODS

Stored electrogram data from 596 spontaneous tachyarrhythmias from 203 patients with Photon DR ICDs were analyzed. Arrhythmias are first classified by the relationship of atrial and ventricular rates (rate branches V<A, V=A, and V>A) followed by additional discriminators: morphology and/or sudden onset if V=A; morphology and/or interval stability if V<A. Data were analyzed for all combinations of ANY and ALL logic.

RESULTS

Sensitivity and specificity were calculated for all spontaneous episodes in each analysis. V=A branch: ALL logic produced unacceptably low sensitivity, whereas morphology provided only similar sensitivity but better specificity than ANY logic. A>V branch: ANY logic provided adequate sensitivity. The combination of morphology only in V=A with interval stability or morphology (ANY logic) in V<A, provided the optimal result with sensitivity, specificity, positive, and negative predictive values of 99%, 79%, 87%, and 98%, respectively.

CONCLUSION

SVT-VT combined discriminators strongly influence dual-chamber SVT-VT discrimination performance. In our study, optimal programming is morphology only in the V=A branch and morphology or interval stability (ANY) in the V<A branch. ALL logic should be used with caution due to loss of sensitivity.

Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator

OBJECTIVES

The purpose of this study was to compare rate-only detection to enhanced detection in a dual-chamber implantable cardioverter-defibrillator (ICD), to discriminate ventricular tachycardia from supraventricular tachycardia.

BACKGROUND

ICDs are highly effective in treating ventricular tachycardia (VT) or ventricular fibrillation (VF). However, they frequently deliver inappropriate therapy during supraventricular tachycardia (SVT).

METHODS

We conducted a randomized clinical trial of detection enhancements in a dual-chamber ICD compared to control (rate-only) detection to discriminate VT from SVT. Detection enhancements included a specific standardized protocol identical for all patients for programming rate stability, sudden onset, atrial-to-ventricular relationship (sudden onset = 9% and rate stability = 10 ms; V > A "on"), and "sustained rate duration" (3 minutes). The primary endpoint was the time to first inappropriate therapy classified by a blinded events committee.

RESULTS

One hundred forty-nine patients had a history of sustained VT or VF. Mean age (+/- SD) was 60 +/- 13 years; 83% were male, and mean ejection fraction was 35 +/- 15%. Control (n = 70) and "enhanced" (n = 79) groups did not differ with regard to age, sex, ejection fraction, or primary arrhythmia. The proportion of patients free of inappropriate therapy over time was significantly higher in the enhanced versus the control group (hazard ratio = 0.47, P = .011). High-energy shocks were reduced from 0.58 +/- 4.23 shocks/patient/month in the control group to 0.04 +/- 0.15 shocks/patient/month in the enhanced group (P = .0425). No patient programmed per protocol failed to receive therapy for VT detected by the ICD (422 VT episodes).

CONCLUSIONS

Standardized programming in a dual-chamber ICD leads to a significant and clinically important reduction in inappropriate therapies compared to rate-only detection and does not compromise safety with respect to appropriate treatment of VT.

The 1+1 Trial

Background— The tachycardia detection interval (TDI) in implantable cardioverter/defibrillators (ICDs) is conventionally programmed according to the slowest documented ventricular tachycardia (VT), with a safety margin of 30 to 60 ms. With this margin, VTs above the TDI may occur. However, longer TDIs are associated with an increased risk of inappropriate therapy. We hypothesized that patients with slow VTs (<200 bpm) may benefit from a long TDI and a dual-chamber detection algorithm compared with a conventionally programmed single-chamber ICD.

Methods and Results— Patients with VTs <200 bpm were implanted with a dual-chamber ICD that was randomly programmed to a dual-chamber algorithm and a TDI of ≥469 ms or to a single-chamber algorithm with a TDI 30 to 60 ms above the slowest documented VT cycle length and the enhancement criteria of cycle length variation and acceleration. The primary combined end point was the number of all inappropriate therapies, VTs above the TDI, and VTs with significant therapy delay (>2 minutes). After 6 months, a crossover analysis was performed. Total follow-up was 1 year. One hundred two patients were included in the study. The programmed TDI was 500±36 ms during the dual-chamber phase and 424±63 ms during the single-chamber phase. For the primary end point (inappropriate therapies, VTs above the TDI, or VTs with detection delay), a moderate superiority of the dual-chamber mode was found: Mann-Whitney estimator=0.6661; 95% CI, 0.5565 to 0.7758; P =0.0040.

Conclusions— Dual-chamber detection with a longer TDI improves VT detection and does not increase the rate of inappropriate therapies despite a considerable increase in tachycardia burden.

High Incidence of Appropriate and Inappropriate ICD Therapies in Children and Adolescents with Implantable Cardioverter Defibrillator

Appropriate and inappropriate therapies of implantable cardioverter defibrillators have a major impact on morbidity and quality of life in ICD recipients, but have not been systematically studied in children and young adults during long-term follow-up. ICD implantation was performed in 20 patients at the mean age of 16 +/- 6 years, 11 of which had prior surgical repair of a congenital heart defect, 9 patients had other cardiac diseases. Implant indications were aborted sudden cardiac death in six patients, recurrent ventricular tachycardia in 9 patient, and syncope in 5 patients. Epicardial implantation was performed in 6 and transvenous implantation in 14 patients. Incidence, reasons and predictors (age, gender, repaired congenital heart disease, history of supraventricular tachycardia, and epicardial electrode system) of appropriate and inappropriate ICD therapies were analyzed during a mean follow-up period of 51 +/- 31 months range 18-132 months. There were a total 239 ICD therapies in 17 patients (85%) with a therapy rate of 2.8 per patient-years of follow-up. 127 (53%) ICD therapies in 15 (75%) patients were catagorized as appropriate and 112 (47%) therapies in 10 (50%) patients as inappropriate, with a rate of 1.5 appropriate and 1.3 inappropriate ICD therapies per patient-years of follow-up. Time to first appropriate therapy was 16 +/- 18 months. Appropriate therapies were caused by ventricular fibrillation in 29 and ventricular tachycardia in 98 episodes. Termination was successful by antitachycardia pacing in 4 (3%) and by shock therapy in 123 episodes (97%). Time to first inappropriate therapy was 16 +/- 17 months. Inappropriate therapies were caused by supraventricular tachycardia in 77 (69%), T wave oversensing in 19 (17%), and electrode defect in 16 episodes (14%). It caused shocks in 87 (78%) and only antitachycardia pacing in 25 episodes (22%). No clinical variable could be identified as predictor of either appropriate or inappropriate ICD therapies. There is a high rate of ICD therapies in young ICD recipients, the majority of which occur during early follow-up. The rate of inappropriate therapies is as high as 47% and is caused by supraventricular tachycardia and electrode complications in the majority of cases. Prospective trials are required to establish preventative strategies of ICD therapies in this young patient population.

Chronic Experiences with a Single Lead Dual Chamber Implantable Cardioverter Defibrillator System

Monitoring of atrial rhythm in patients implanted with ICDs may improve accuracy in identifying supraventricular arrhythmias and, therefore, prevent inappropriate therapies. Since difficulties were found in dual chamber ICDs with separate leads, a new designed single lead dual chamber ICD system was tested. Twenty-five patients implanted with a Deikos A+ (single coil defibrillation lead with two atrial sensing rings combined with a dual chamber ICD with a high amplifying atrial channel) were tested. Atrial and ventricular signals were analyzed during sinus rhythm (SR) and sinus tachycardias (STs), atrial flutter and AF, and VT or VF. Follow-ups were performed after 1, 3, 6, 9, and 12 months after implantation. Analysis of EGM amplitudes of stored episodes revealed that atrial signals during atrial flutter (2.1 +/- 0.51 mV) were comparable to those of ST (2.2 +/- 0.5 mV). Atrial amplitudes during AF were significantly lower (0.81 +/- 0.5 mV, P<0.01). During VF atrial "sinus" signals (2 +/- 0.8 mV) were stable. Ventricular parameters did not differ from a standard ICD lead; defibrillation threshold was 11.4 +/- 4.5 J (16 patients). During intraoperative and prehospital discharge measurements, 97.1% of SR-P waves and 99.2% of atrial flutter waves were detected correctly. In AF 91.11% of atrial signals were detected. Analysis of 505 stored episodes showed that 96.8% of ST and 100% of atrial flutter and 100% of AF episodes have been classified correctly and no underdetection of VT/VF was found. The first experiences with the new VDD-ICD system show an increase of the specificity to detect ventricular tachycardias to a level comparable to dual chamber ICDs with two leads. The reliability of this system has to be proven in a prospective randomized study.

Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators

Morphology Discrimination is a discriminator based on QRS morphology analysis that has been recently implemented in dual chamber implantable cardioverter defibrillators (ICDs). Detected events are initially classified according to median atrial and ventricular rates (Rate Branch). Then, a series of discriminators (Morphology Discrimination, Stability, Sudden Onset) analyze the rhythm according to specific criteria and the number of discriminators required for VT diagnosis (i.e., requiring "any" or "all" of the specific discriminators to indicate VT). The discriminating accuracy of the algorithm was evaluated in 645 detections recorded during the follow-up of 25 patients. The overall specificity for 397 supraventricular arrhythmias was 73.5% (292/397) with the tachycardia diagnosis criteria set to "any" and 90.9% (361/397) with the tachycardia diagnosis criteria set to "all." Sensitivity for VT was 100% and 98.7% (231/234) with the tachycardia diagnosis criteria set to "any" and "all," respectively. With the tachycardia diagnosis criteria set to "any," specificity for atrial fibrillation was 88.6%, for atrial flutter 40.3%, for atrial tachycardia 0%, and for sinus tachycardia 97.0%. With the tachycardia diagnosis criteria set to "all," specificity for atrial fibrillation was 92.40%, for atrial flutter 93.5%, for atrial tachycardia 54.7%, and for sinus tachycardia 99.0%. The contribution of Morphology Discrimination was crucial to improve the specificity of the Rate Branch algorithm. The implementation of Morphology Discrimination in a dual chamber ICD with Rate Branch rhythm classification allows the attainment of high specificity and high sensitivity for ventricular tachyarrhythmias.

Current status of the implantable cardioverter-defibrillator

Clinical trials have established the superiority of the implantable cardioverter-defibrillator (ICD) over antiarrhythmic drug therapy in survivors of sudden cardiac death and in high-risk patients with coronary artery disease. The ICD has evolved to overcome the limitation of earlier devices that required thoracotomy for implantation and were fraught with inappropriate shock delivery. Current ICDs are implanted in a similar manner to cardiac pacemakers and incorporate sophisticated rhythm-discrimination algorithms to prevent inappropriate therapy. Managing the patient with an ICD requires an understanding of the multiprogrammable features of modern devices. Drug interactions and potential sources of electromagnetic interference may adversely affect ICD function. Driving restrictions may be necessary under certain conditions. The cost-effectiveness of ICD therapy appears favorable, given the marked survival benefit seen in randomized trials relative to antiarrhythmic drug treatment. The growing number of ICD recipients necessitates an understanding of the specialized features of the modern ICD and the role of device therapy in clinical practice.

Dual chamber arrhythmia detection in the implantable cardioverter defibrillator

INTRODUCTION

Dual chamber implantable cardioverter defibrillator (ICD) technology extended ICD therapy to more than termination of hemodynamically unstable ventricular tachyarrhythmias. It created the basis for dual chamber arrhythmia management in which dependable detection is important for treatment and prevention of both ventricular and atrial arrhythmias.

METHODS AND RESULTS

Dual chamber detection algorithms were investigated in two Medtronic dual chamber ICDs: the 7250 Jewel AF (33 patients) and the 7271 Gem DR (31 patients). Both ICDs use the same PR Logic algorithm to interpret tachycardia as ventricular tachycardia (VT), supraventricular tachycardia (SVT), or dual (VT+ SVT). The accuracy of dual chamber detection was studied in 310 of 1,367 spontaneously occurring tachycardias in which rate criterion only was not sufficient for arrhythmia diagnosis. In 78 episodes there was a double tachycardia, in 223 episodes SVT was detected in the VT or ventricular fibrillation zone, and in 9 episodes arrhythmia was detected outside the boundaries of the PR Logic functioning. In 100% of double tachycardias the VT was correctly diagnosed and received priority treatment. SVT was seen in 59 (19%) episodes diagnosed as VT. The causes of inappropriate detection were (1) algorithm failure (inability to fulfill the PR<RP condition in atrial tachyarrhythmias with 1:1 AV conduction, and far-field R wave sensing intermittently present during sinus tachycardia); (2) programming settings (atrial fibrillation/atrial flutter with ventricular rate above the SVT limit); and (3) algorithm limitations (atrial tachycardia with ventricular rate around the shortest programmable SVT limit and SVT redetection following VT therapy). Programming measures improved detection ability in 13 of 59 of inappropriately detected arrhythmias.

CONCLUSION

Dual chamber detection algorithms evaluated in a subset of diagnostically difficult arrhythmias allow safe detection of double tachycardias but require further extension and programmability to improve VT:SVT discrimination rules.

Implantable Cardioverter Defibrillator: Current Progress and Management

With greater technologic advances during the past decade, use of the implantable cardioverter defibrillator (ICD) has increased to more than 200,000 implants worldwide to date. Indications for ICD implant have expanded to include both patients who have survived sudden cardiac death (secondary prevention of cardiac arrest) and those who are at high risk for experiencing lethal arrhythmias (primary prevention of cardiac ar rest). Thus, it is likely that physicians will encounter defibrillators in their clinical practice and must be familiar with their indications for implant, basic opera tion, and long-term management of devices. Several prospective clinical trials have recently shown the long- term efficacy of ICD therapy at aborting sudden death in the high-risk patient population. Although still evolving, general guidelines and indications for ICD implant have been put forth and are discussed in this review. From the first defibrillation in humans during surgery in 1947 to the sophisticated dual-chamber pacing and memory functions of the modern device, ICD development has led to ever smaller devices with more complex technol ogy. The implant procedure of current ICDs parallels that used to place pacemakers. However, the anesthe sia team plays a vital role in initial ICD implantation by monitoring cardiopulmonary status during defibrilla tion threshold (DFT) testing. Additionally, long-term management of ICDs often requires repeat DFT testing with anesthesia involvement. Finally, possible electro magnetic (environmental) interactions with the ICD of which physicians should be aware are described in this article.

Morphology discriminator feature for enhanced ventricular tachycardia discrimination in implantable cardioverter defibrillators

The morphology discriminator (MD) feature is an electrogram template matching algorithm that intends to improve tachycardia discrimination in implantable cardioverter defibrillators (ICDs). The aim of this study was to evaluate the performance of this feature during spontaneously occurring ventricular and supraventricular tachyarrhythmias and exercise induced sinus tachycardia. Twenty-three patients (20 men, 3 women; mean age 54.3 +/- 13.8 years) with pectorally implanted Ventritex Contour MD, Angstrom MD, and Profile MD ICDs were studied. The stability of the acquired morphology template and performance of the algorithm during spontaneous tachyarrhythmias were evaluated at follow-up. A treadmill exercise test was performed in 16 patients along with continuous telemetric monitoring of matching scores. A satisfactory template could be acquired at baseline in 22 (96%) patients. Variations in electrogram morphology necessitated new template acquisition in seven (30%) patients at first follow-up (6-8 weeks postimplant). During a mean follow-up of 9.1 +/- 3.7 months, 56 ventricular tachycardia (VT) and 15 supraventricular tachycardia episodes (sinus tachycardia in two-thirds) in 11 patients were all appropriately discriminated by the MD feature. Exercise testing showed appropriate discrimination of sinus tachycardia in 15 (94%) of 16 patients. A common observation was postshock changes in electrogram morphology that resulted in transient mismatch with the template. In conclusion, the recently introduced MD feature in ICDs has a high sensitivity for detection of VT and high specificity for rejection of sinus tachycardia. Postshock changes in electrogram morphology have been observed that may cause inappropriate redetection. Marked variations of electrogram morphology over time may be a concern in some patients, especially during lead maturation.

Methods of minimizing inappropriate implantable cardioverter-defibrillator shocks

As more and more patients receive complex implantable cardioverter-defibrillators (ICDs), profound knowledge about the incidence of inappropriate device therapy, the reasons it happens, and the possibilities for prevention is crucial. In this article, the most important prevention algorithms incorporated in current ICD models and their advantages and handicaps are discussed in detail, which should help to guide the device selection for a particular patient. Also, emphasis is put on adjunctive drug therapy and interventional treatment strategies, which are crucial in managing patients with inappropriate ICD shocks.

Implantable dual-chamber cardioverter-defibrillator-pacemaker

The fifth generation of implantable cardioverter-defibrillators offer enhanced modes of detection of atrial and ventricular arrhythmias, antitachycardia pacing and shocks, multiprogrammability, intracardiac electrogram storage, and all functions of antibradycardia dual-chamber pacing including rate responsiveness and mode switching. There is no consensus on the indications for dual-chamber pacemaker defibrillator systems. This review focuses on the four major options of newer devices that might benefit patients: 1) permanent dual-chamber pacing in ischemic coronary disease patients, 2) detection and management of atrial fibrillation or other atrial tachyarrhythmias, 3) some newer indications for pacing, and 4) the suppression of inappropriate interventions. On the basis of published data, newer indications for the dual-chamber systems, advantages and limitations, and future perspectives are discussed.

Comparison of therapy detection times between implantable cardioverter defibrillators with standard dual- and single-chamber pacing

Previous implantable cardioverter defibrillators (ICDs) required patients in need of dual-chamber (DDD) pacing for improved hemodynamic status to undergo implantation of separate devices to treat bradycardia and/or ventricular arrhythmias. An investigation was conducted to verify the performance of a new ICD that combines both therapies.Sixty-nine patients at 17 European and Canadian centers were implanted with VENTAK AV models 1810/1815, ICD's that includes DDD pacing and algorithms designed to differentiate between atrial and ventricular arrhythmias. 36 of the cohort were compared to 32 patients tested at six centers with an external test device (VENTAK MINI). In both cohorts detection times were calculated for ventricular fibrillation (VF) induced at implant. The mean detection times (DT) from the VENTAK AV device were compared to the DT from the VENTAK MINI device. Patient characteristics of the VENTAK AV and the VENTAK MINI control groups were similar. Mean VF detection time (+/-SD) with the VENTAK AV device was 2.21 +/- 0.54 seconds, as compared with 1.87 +/- 0.62 seconds with the VENTAK MINI (p < 0.01), indicating that the difference in means did not exceed one second. The VENTAK AV system function did not demonstrate interaction with the pacemaker function, as indicated by the clinical significance with the detection times of the study device. The difference in detection times between cohorts did not statistically exceed one second. Appropriate detection of the new ICD was not compromised by the addition of the dual-chamber pacing therapy.

Dual chamber implantable cardioverter defibrillator benefits and limitations

Dual chamber ICD capable of providing dual chamber pacing (DDD) and ventricular arrhythmia therapy is now available. We report our experience of clinical performance of dual chamber ICDs amongst Chinese population.

METHODS

9 patients (6 men and 3 women) received dual chamber ICDs, mean age 50 +/- 18.8 years. The indications were ventricular fibrillation (VF) [5], hemodynamic intolerant ventricular tachycardia (VT) [3] and unexplained syncope plus positive induction of VF [1]. The underlying cardiac pathology were congenital LQT syndrome(1), hypertrophic cardiomyopathy [2], coronary artery disease [2], rheumatic valvular disease [1], Brugada syndrome [1], arrhythmogenic right ventricular dysplasia [1] and idiopathic VF [1]. Four patients have documented paroxysmal atrial fibrillation (AF). All patients have defibrillation thresholds (DFT) determined with a binary search protocol starting at 12 joules (J) at implantation.

RESULTS

A total of 34 episodes of VF were induced at implantation with mean DFT 13.8 +/- 7 J. The average shocking impedance was 40 +/- 3.6 Omega. The mean acute P wave measured 3.3 +/- 1.3 mV and R wave measured 13.2 +/- 3.2 mV. Atrial and ventricular thresholds, at pulse width 0.5 ms, averaged 0.8 +/- 0.4 V and 0.4 +/- 0.2 V. During follow-up period, 16 episodes of VF were documented and were successfully treated with the first programmed shock. In the patient with LQT syndrome, DDD was initiated to prevent pause-dependant VF. Three episodes of inappropriate therapy (15.8%) were delivered. One patient experienced 2 shocks after exercise. Stored electrograms showed sinus tachycardia with first degree heart block which was misdiagnosed as VT with retrograde 1:1 conduction. Another inappropriate therapy occurred with AF with fast ventricular response within the VF zone and VT therapy inhibitor was disabled.

CONCLUSION

Dual chamber ICD allows combined benefits of DDD and VT/VF therapy. Storage of both atrial and ventricular electrograms provide more information in elucidation of nature of dysarrhythmias. Inappropriate shocks, though reduced, are still possible and the rigid algorithms of SVT discrimination from VT will need further published.

Correlation waveform analysis to discriminate monomorphic ventricular tachycardia from sinus rhythm using stored electrograms from implantable defibrillators

In order to examine whether a template-matching program utilizing correlation waveform analysis (CWA) might be used to discriminate monomorphic ventricular tachycardia (MMVT) from sinus rhythm (SR) in patients with implantable cardioverter defibrillators (ICDs), we studied stored episodes of induced MMVT in 25 patients and compared them to corresponding stored SR electrograms. We calculated mean correlation coefficients for SR beats against an SR template chosen within each sinus episode, induced MMVT beats against an induced MMVT template within each ventricular tachycardia episode, and induced MMVT beats against the original SR template. For each patient, the 99.5% lower confidence limit for the mean correlation coefficient of SR beats versus an SR template (patient-specific method) or the empirical correlation coefficient value 0.9 were selected as threshold values to discriminate induced MMVT from SR. The mean correlation coefficient for induced MMVT beats versus the original SR template for each patient was subtracted from both threshold values. A positive value is defined as accurate discrimination of induced MMVT from SR. Using 0.9 for a threshold cut off, 21 of 25 episodes of induced MMVT were accurately labeled with a sensitivity of 84%. Using the patient-specific method, we were able to correctly distinguish 23 of 25 episodes of induced MMVT from SR with a sensitivity of 92%. There was no statistically significant difference between the patient-specific or empirical methods in detecting MMVT (P 50.4). This is the first demonstration using stored intracardiac electrograms from ICDs that CWA is able to discriminate MMVT from SR with high sensitivity. Such a template-matching system may be used for off-line analysis or real-time rhythm discrimination.

Is inappropriate therapy a resolved issue with current implantable cardioverter defibrillators?

Patients with an implantable cardioverter defibrillator (ICD) can undergo inappropriate therapies if electrical activity not originating in the ventricle is wrongly recognized as ventricular by the device. Inappropriate therapy can be the result of detection of supraventricular tachycardias or over-sensing of other artifacts by the device. Enhanced detection criteria in third-generation ICD have been implemented to recognize fast supraventricular arrhythmias. Analysis of the use of these criteria in patients with an ICD has shown that arrhythmias detected in the ventricular tachycardia zone are frequently supraventricular (193 supraventricular of 690 tachycardia episodes in 23 of 59 patients). Use of sudden onset was very effective in detecting sinus tachycardia (65 of 67 episodes) and stability was very useful in detecting atrial fibrillation (31 of 32 episodes). However sensitivity in detecting ventricular tachycardia was only 90% (451 of 497 episodes). Application of the sustained, rate duration criteria allowed appropriate treatment of all ventricular tachycardia episodes, increasing sensitivity to 100%; however, specificity in appropriate nontreatment of supraventricular episodes decreased from 96% to 83%. Subsequent analysis of different algorithms showed that sudden onset > 9% and stability < 40 msec was the algorithm with the best specificity and sensitivity. Programming sudden onset and stability detection criteria with a sustained, rate duration safety net for triggering tachycardia therapy results in appropriate device management in most patients with supraventricular and relatively slow ventricular tachycardia.

Managing atrial tachyarrhythmias in patients with implantable cardioverter defibrillators

The implantable cardioverter defibrillator (ICD) is accepted as the therapy of choice in preventing sudden cardiac death. Multiple studies, such as Antiarrhythmics Versus Implantable Defibrillators (AVID), the Canadian Implantable Defibrillator Study (CIDS), the Cardiac Arrest Study Hamburg (CASH), and the Multicenter Automatic Defibrillator Implantation Trial (MADIT), have shown a substantial benefit in survival rates for patients treated with ICDs compared with antiarrhythmic drug treatment. The detection of spontaneous ventricular tachycardias (VT) is based primarily on the programmed heart rate for intervention of the device. Supraventricular tachycardias (SVTs) cause unnecessary therapy delivery in about 10-20% of patients with ICDs. ICD therapy needs to be improved to become more specific for VT detection, by implementing algorithms that discriminate between VTs and SVTs. The enhanced detection criteria in currently available ICD devices are able to decrease the rate of unnecessary therapy to < 5% of patients. Atrial tachyarrhythmias can be managed with programmable features of the device, antiarrhythmic drug treatment, and in rare cases, ablation procedures. Dual-chamber ICDs, requiring an additional atrial lead, are indicated in specific situations of slow VT and concurrent, continuous SVTs at very similar heart rates. Using all these options, SVTs can be managed to achieve an acceptably low incidence of unnecessary therapy delivery in < 5% of ICD patients.

A preview of implantable cardioverter defibrillator systems in the next millennium: an integrative cardiac rhythm management approach

The implantable cardioverter defibrillator (ICD), a primary therapeutic option for preventing sudden cardiac death, has rapidly evolved since being introduced clinically in 1980. Technologic advances in several key areas have enabled ICDs to provide more sophisticated rhythm management. Recent emphasis has been placed on dual-chamber ICDs possessing adaptive-rate pacing capabilities. Adoption of dual-chamber ICD systems has been rapid. The capabilities of future ICD systems will be governed by an integrative strategy that brings together sets of features specifically targeted at multifaceted rhythm disorders. The addition of atrial therapy will require more sophisticated rhythm discrimination algorithms. ICD technology will improve on several fronts including leads, integrated circuits, batteries, and capacitors. Additionally, state-of-the-art pacemaker technology will continue to be incorporated into ICDs. As these new ICD systems become increasingly sophisticated from an engineering viewpoint, tremendous emphasis will be placed on decreasing the complexity of programming, device interrogation, and patient monitoring during routine patient follow-up. Vast improvements in ICD programming systems may ultimately permit the 1-minute follow-up.

Efficacy and safety of the initial use of stability and onset criteria in implantable cardioverter defibrillators

INTRODUCTION

Inappropriate therapies are the most frequent adverse event in patients with implantable cardioverter defibrillators (ICDs). Most ICDs offer a stability criterion to discriminate ventricular tachycardia (VT) from atrial fibrillation and an onset criterion to discriminate VT from sinus tachycardia. The efficacy and safety of these criteria, if used immediately after implantation, is unknown.

METHODS AND RESULTS

In a case control study, 87 patients in whom stability and onset criteria had been activated immediately after ICD implantation were matched to 87 patients in whom these criteria had not been activated. The groups were matched for known predictors of inappropriate therapies. With stability and onset criteria off, 24 patients (28%) received inappropriate therapies due to atrial fibrillation (n = 14) or sinus tachycardia (n = 11); with stability and onset on, only 11 patients (13%) were treated by the ICD due to atrial fibrillation (n = 5) or sinus tachycardia (n = 7) (log rank: P = 0.029). Five patients suffered inappropriate therapies despite the fact that onset (n = 4) or stability (n = 1) criteria were not fulfilled once tachycardias continued for a prespecified duration. Only one patient experienced a failure to detect VT due to the onset criterion; none because of stability.

CONCLUSION

The immediate use of stability and onset criteria after ICD implantation reduces inappropriate therapies due to atrial fibrillation and sinus tachycardia. Because of the potential for underdetection of VT, this approach should be limited to tachycardia rates hemodynamically tolerated by the patient.

Technologic advances in implantable cardioverter defibrillators

Multiple technologic advances in the implantable cardioverter defibrillator (ICD) have resulted in smaller size, easier implantation, and improved detection, therapy, and stored diagnostic information. Advanced dual-chamber ICDs are currently available that allow dual-chamber rate-responsive pacing with mode switching, enhanced detection algorithms, antitachycardia pacing, low-energy cardioversion, high-energy shocks, and extensive diagnostics. Based on improvements in lead systems and improved energy waveforms, almost all devices are being implanted with nonthoracotomy leads in the pectoralis area. The results of recent clinical trials have expanded indications for the ICD for primary and secondary prevention of sudden cardiac death. With advances in capacitor and battery technology coupled with improved lead systems and waveform resulting in lower defibrillation thresholds, it is likely that lower-output, smaller devices will be developed. In the future, ICDs may have expanded indications and may incorporate physiologic sensors to access hemodynamic significance of arrhythmias and algorithms for prediction and prevention of cardiac arrhythmias.

A new defibrillator discrimination algorithm utilizing electrogram morphology analysis

Inappropriate therapies delivered by implantable cardioverter defibrillators (ICDs) for supraventricular arrhythmias remain a common problem, particularly in the event of rapidly conducted atrial fibrillation or marked sinus tachycardia. The ability to differentiate between ventricular tachycardia and supraventricular arrhythmias is the major goal of discrimination algorithms. Therefore, we developed a new algorithm, SimDis, utilizing morphological features of the shocking electrograms. This algorithm was developed from electrogram data obtained from 36 patients undergoing ICD implantation. An independent test set was evaluated in 25 patients. Recordings were made in sinus rhythm, sinus tachycardia, and following the induction of ventricular tachycardia and atrial fibrillation. The arrhythmia complex is defined as wide if the duration is at least 30% greater than the template in sinus rhythm. For narrow complexes, four maximum and minimum values were measured to form a 4-element feature vector, which was compared with a representative feature vector during normal sinus rhythm. For each rhythm, any wide complex was classified as ventricular tachycardia. For narrow complexes, the second step of the algorithm compared the electrogram with the template, computing similarity and dissimilarity values. These values were then mapped to determine if they fell within a previously established discrimination boundary. On the independent test set, the SimDis algorithm correctly classified 100% of ventricular tachycardias (27/27), 98% of sinus tachycardias (54/55), and 100% of episodes of atrial fibrillation (37/37). We conclude that the SimDis algorithm yields high sensitivity (100%) and specificity (99%) for arrhythmia discrimination, using the computational capabilities of an ICD system.

Intracardiac QRS electrogram width--an arrhythmia detection feature for implantable cardioverter defibrillators: exercise induced variation as a base for device programming

Delivery of inappropriate therapy of implantable cardioverter defibrillators (ICD) due to inaccurate arrhythmia detection represents a major clinical problem. Different arrhythmia detection criteria such as the "stability" of the cycle length or the suddenness of "onset" of tachycardia have been implemented in ICD software to prevent inappropriate therapy. The new Medtronic model 7223Cx ICD offers an additional detection parameter (QRS width), which reflects changes in the duration of ventricular depolarization as a tool to distinguish supraventricular from ventricular tachycardias. Although this criterion can be programmed based on ECG parameters derived from resting ECGs, this may not be sufficient since QRS width is subject to considerable changes due to transient myocardial ischemia, changes in autonomic tone, or frequency dependent effects of antiarrhythmic drugs. The present study aimed to determine frequency dependent changes in QRS width in individual patients at rest and during symptom-limited exercise testing in 16 patients with documented ventricular tachycardia (N = 13) or ventricular fibrillation (N = 3). The optimal EGM slew threshold and the individual variation of QRS width were determined. Measurements obtained at the end of the implantation procedure were compared to those performed at hospital discharge. The majority of patients showed a wider variation in QRS duration as measured from 30 consecutive cycles during exercise as compared to rest. For example, the QRS range (i.e., the difference between the maximal and the minimal QRS width measured) averaged 7 +/- 3 ms at rest and increased to 11 +/- 3 ms during exercise (P = 0.004) with an increase of > or = 4 ms observed in 11 (69%) of 16 patients. In 13 (81%) of 16 patients a reprogramming of at least one QRS width parameter from its value at the time of implantation was necessary. Thus, the QRS width measured from the intracardiac EGM shows significant intraindividual variations in different physiological conditions. For optimal programming of the QRS width parameter, measurements obtained during exercise are important.

Discrimination of sinus rhythm, atrial flutter, and atrial fibrillation using bipolar endocardial signals

INTRODUCTION

Analysis of endocardial signals obtained from an electrode located in the right atrium as realized in newly designed dual chamber, implantable cardioverter defibrillators might be used to provide additional therapeutic options, such as overdrive pacing or low-energy atrial cardioversion for the treatment of concomitant atrial flutter (AFL) or atrial fibrillation (AF). Therefore, we developed a computer algorithm for discrimination of normal sinus rhythm (NSR), AFL, and AF that may lead to adequate differential therapy of atrial tachyarrhythmias in an automated mode.

METHODS AND RESULTS

During an electrophysiologic study, bipolar endocardial signals from the high right atrium were obtained in 28 patients during sustained AFL or AF and after restoration of NSR. A total of 286 data segments of 5-second duration were recorded (NSR: 96, AFL: 86, AF: 104). Mean atrial cycle length (MCL), standard deviation of mean atrial cycle length (SDCL), and index of irregularity (IR), defined as the ratio between MCL and SDCL, were calculated for each data segment. A cutoff of 315 msec for MCL allowed discrimination of NSR from atrial tachyarrhythmias with 100% sensitivity and specificity. For discrimination of AF from AFL by using SDCL, a cutoff value of 11.5 msec led to a sensitivity of 99% and a specificity of 90%. Best discrimination of AF from AFL was found for the criterion IR > or = 7.5%, resulting in a sensitivity of 100% with a specificity of 95% for AF detection.

CONCLUSION

The investigated algorithm provides discrimination of NSR, AFL, and AF with high sensitivity and specificity. Incorporation of this algorithm in an implantable automated antitachycardia device may lead to adequate differential therapy in patients suffering from spontaneous episodes of AF and AFL.

Enhanced detection criteria in implantable defibrillators

INTRODUCTION

Enhanced detection criteria in third-generation implantable defibrillators have been implemented to avoid inappropriate therapy of fast supraventricular arrhythmias. We prospectively analyzed the use of these criteria in patients with an implantable defibrillator with electrogram storing capability.

METHODS AND RESULTS

In 82 consecutive patients with a Guidant-CPI implantable defibrillator, sudden onset > 9% and stability < 40 msec were systematically programmed in zone 1 of therapy together with a sustained rate duration security mechanism. All detected tachycardia episodes were analyzed. The study population consisted of 59 patients who had at least one episode of tachycardia detected in zone 1 during follow-up. The tachycardia rate in zone 1 never exceeded 210 beats/min. Twenty patients had no episodes during follow-up, and three patients had episodes detected exclusively in zone 2 of therapy. Supraventricular arrhythmias were detected frequently in the ventricular tachycardia zone (193 of 690 tachycardia episodes in 23 of 59 patients). Use of sudden onset was very effective in detecting sinus tachycardias (65 of 67 episodes), and stability was very useful in detecting atrial fibrillation (31 of 32 episodes). However, sensitivity in detecting ventricular tachycardia was only 90% (451 of 497 episodes). Application of the sustained rate duration criterion allowed appropriate treatment of all ventricular tachycardia episodes, increasing sensitivity to 100%; however, specificity in appropriate nontreatment of supraventricular decreased from 96% to 83%. Subsequent analysis of different algorithms applied to our data showed that sudden onset > 9% and stability < 40 msec was the algorithm with the best specificity and sensitivity.

CONCLUSION

Programming sudden onset and stability detection criteria with a sustained rate duration safety net for triggering tachycardia therapy results in appropriate device management in most patients with supraventricular and slow (< 210 beats/min) ventricular tachycardias.

A new classification algorithm for discrimination of ventricular from supraventricular tachycardia in a dual chamber implantable cardioverter defibrillator

INTRODUCTION

The high incidence of inappropriate therapies due to supraventricular tachycardia remains a major unsolved problem of implantable cardioverter defibrillators. We report a new detection formula for discrimination of ventricular tachycardia from supraventricular tachycardia in a patient with a dual chamber implantable cardioverter defibrillator and a new atrioventricular classification algorithm.

METHODS AND RESULTS

The enhanced detection algorithm performs a stepwise arrhythmia analysis. The rhythm is first classified on the basis of cycle length. Each episode is then classified as supraventricular or ventricular on the basis of atrioventricular association, stability of circle length, and origin of acceleration. Sophisticated diagnostic information is provided by atrioventricular markers and electrogram recordings. Successful discrimination of two spontaneous episodes of ventricular tachycardia and supraventricular tachycardia is demonstrated.

CONCLUSION

This new dual chamber detection algorithm may significantly improve the specificity of tachyarrhythmia detection without sacrificing sensitivity, thereby reducing the number of spurious shocks in patients with recurrent supraventricular tachycardias. Further studies are needed to assess the sensitivity and specificity of this detection algorithm.

Antiarrhythmic therapy--future trends and forecast for the 21st century

This article discusses recent changes in antiarrhythmic therapy, with a focus on nonpharmacologic therapy (electrode catheter ablation, implantable cardioverter-defibrillators [ICDs]), and puts them into perspective for the coming years. The treatment of supraventricular tachycardias and tachycardia involving accessory pathways is likely to remain the domain of catheter ablation. With promising new techniques under investigation, the spectrum of arrhythmias that can be cured will probably be expanded. Treatment of life-threatening ventricular arrhythmias is likely to remain the domain of the ICD in the foreseeable future. With the safety net of the ICD in place, new antiarrhythmic drugs or other forms of antiarrhythmic therapy can be developed and tested.

[The current status of implantable automatic defibrillators]

The implantable cardioverter defibrillator has become an important therapy for patients with sustained or life threatening ventricular arrhythmias. Although the concept for the implantable cardioverter defibrillator originated in the late 1960s, the first device was implanted in humans in 1980. Since then, the technology has improved rapidly the design, function and reliability of the devices have been greatly modified. There are currently five companies dealing with defibrillators in Spain incorporating multiple options in defibrillation, pacing and sensing capabilities. New devices with atrioventricular pacing and atrial defibrillation possibilities will soon become available. The purpose of this article is to review the principal functions of implantable cardioverter defibrillators currently available.

[New algorithms for discrimination between supraventricular and ventricular tachyarrhythmias in patients with implantable cardioverter/defibrillator]

The current therapy with implantable cardioverter/defibrillators (ICD) is lacking specificity. The technical concept of arrhythmia detection, as a single channel ventricular rate threshold does not provide a clear differentiation between supraventricular and ventricular rhythms. Nearly 25% of all ICD-therapies are related to a false positive detection of supraventricular arrhythmias.The use of alternative, non rate based detection algorithms is limited due to the reduced long-term stability of the sensors and due to a high battery drain. Based on the current concept of arrhythmia detection, the use of additional timing algorithms as the variability of consecutive RR-cycle length ("Rate-Stability") and the detection of a sudden acceleration in the ventricular rate ("Rate-Onset") provide a clinical relevant increase in specificity in ICD-therapy. A further class of detection algorithms uses the morphologic assessment of intracardiac electrograms. Despite the fact that these morphology based algorithms have shown a high sensitivity and specificity in the discrimination between ventricular and non-ventricular rhythms, only one algorithm was implemented in ICD-generators and the clinical importance in ICD-therapy was very small. In 1995 a new morphology based detection algorithm was introduced in ICD-therapy. The "width criterion" is based on the measurment of the duration of the intracardiac signal. In 1995 and 1996 the first two series of a dual chamber ICD system were introduced in clinical ICD-therapy. These devices provide a two-channel atrio-ventricular arrhythmia detection in connection with a DDD antibradycardia pacing therapy. The use of DDD-ICD systems is expected to be a great step forward to enhance diagnostic specificty. A number of rate and timing detection algorithms and algorithms comparing the assoziation of atrial and ventricular signals may improve the discrimination between supraventricular and ventricular tachyarrhythmias. The future implementation of additional morphology based detection algorithms in DDD-ICD systems may solve the problem of the limited detection specificity in clinical ICD-therapy.